Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab vs Chemotherapy in Stage IV Squamous NSCLC
NCT02409355Phase 3Terminated
- Sponsor
- Roche
- Start
- May 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of atezolizumab in squamous cell carcinoma of the lung (SCCL), sponsored by Roche. Started May 2015; status: terminated.
02
Drugs
atezolizumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02409355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409355.